Biomark Diagnostics Stock Performance
| BMKDF Stock | USD 0.36 0.01 2.86% |
On a scale of 0 to 100, BioMark Diagnostics holds a performance score of 10. The firm shows a Beta (market volatility) of 0.59, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioMark Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding BioMark Diagnostics is expected to be smaller as well. Please check BioMark Diagnostics' downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether BioMark Diagnostics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioMark Diagnostics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, BioMark Diagnostics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 877.7 K | |
| Total Cashflows From Investing Activities | -59.2 K |
BioMark |
BioMark Diagnostics Relative Risk vs. Return Landscape
If you would invest 23.00 in BioMark Diagnostics on November 10, 2025 and sell it today you would earn a total of 13.00 from holding BioMark Diagnostics or generate 56.52% return on investment over 90 days. BioMark Diagnostics is currently producing 0.8844% returns and takes up 6.7991% volatility of returns over 90 trading days. Put another way, 61% of traded otc stocks are less volatile than BioMark, and 83% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioMark Diagnostics Target Price Odds to finish over Current Price
The tendency of BioMark OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.36 | 90 days | 0.36 | about 21.55 |
Based on a normal probability distribution, the odds of BioMark Diagnostics to move above the current price in 90 days from now is about 21.55 (This BioMark Diagnostics probability density function shows the probability of BioMark OTC Stock to fall within a particular range of prices over 90 days) .
BioMark Diagnostics Price Density |
| Price |
Predictive Modules for BioMark Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioMark Diagnostics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioMark Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioMark Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioMark Diagnostics is not an exception. The market had few large corrections towards the BioMark Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioMark Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioMark Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.81 | |
β | Beta against Dow Jones | 0.59 | |
σ | Overall volatility | 0.05 | |
Ir | Information ratio | 0.12 |
BioMark Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioMark Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioMark Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioMark Diagnostics is way too risky over 90 days horizon | |
| BioMark Diagnostics has some characteristics of a very speculative penny stock | |
| BioMark Diagnostics appears to be risky and price may revert if volatility continues | |
| BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 43.93 K. Net Loss for the year was (1.45 M) with profit before overhead, payroll, taxes, and interest of 43.93 K. | |
| BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
BioMark Diagnostics Fundamentals Growth
BioMark OTC Stock prices reflect investors' perceptions of the future prospects and financial health of BioMark Diagnostics, and BioMark Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioMark OTC Stock performance.
| Return On Asset | -1.45 | |||
| Operating Margin | (15.72) % | |||
| Current Valuation | 12.8 M | |||
| Shares Outstanding | 83.29 M | |||
| Price To Earning | (8.80) X | |||
| Price To Sales | 105.81 X | |||
| Revenue | 43.93 K | |||
| EBITDA | (1.22 M) | |||
| Cash And Equivalents | 364.96 K | |||
| Total Debt | 96.3 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.2 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 1.47 M | |||
| Retained Earnings | (3.47 M) | |||
| Current Asset | 19 K | |||
| Current Liabilities | 480 K | |||
About BioMark Diagnostics Performance
By analyzing BioMark Diagnostics' fundamental ratios, stakeholders can gain valuable insights into BioMark Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioMark Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioMark Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.Things to note about BioMark Diagnostics performance evaluation
Checking the ongoing alerts about BioMark Diagnostics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for BioMark Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioMark Diagnostics is way too risky over 90 days horizon | |
| BioMark Diagnostics has some characteristics of a very speculative penny stock | |
| BioMark Diagnostics appears to be risky and price may revert if volatility continues | |
| BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 43.93 K. Net Loss for the year was (1.45 M) with profit before overhead, payroll, taxes, and interest of 43.93 K. | |
| BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
- Analyzing BioMark Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioMark Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining BioMark Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioMark Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioMark Diagnostics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of BioMark Diagnostics' otc stock. These opinions can provide insight into BioMark Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioMark OTC Stock analysis
When running BioMark Diagnostics' price analysis, check to measure BioMark Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMark Diagnostics is operating at the current time. Most of BioMark Diagnostics' value examination focuses on studying past and present price action to predict the probability of BioMark Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMark Diagnostics' price. Additionally, you may evaluate how the addition of BioMark Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |